Why Mpox Exposed a Financing Gap, Not Just a Surveillance Gap in Central Africa
The mpox clade I emergency showed that African countries can detect zoonotic spillover faster than the world can fund the response. Closing that gap is a financing and diplomacy problem as much as a laboratory one.
When mpox clade I was declared a public health emergency of continental and international concern, the headlines focused on case counts. The more important story was quieter: national and regional laboratories in Central and East Africa identified the shift in transmission dynamics with real sophistication. The gap wasn't detection. It was what happened in the weeks after detection, when diagnostic capacity, vaccine allocation, and cross-border case management all depended on financing decisions made far from the outbreak.
Detection is no longer the bottleneck
A decade of investment in genomic sequencing, community health worker networks, and regional public health institutions has changed what's possible on the ground. Countries that once had to send samples abroad for confirmation can now sequence locally within days. That is a genuine achievement, and it's one that often goes unrecognized in global health narratives that still default to a story about weak surveillance in the Global South.
The real constraint now sits downstream: how quickly funding, vaccine doses, and technical personnel can move once a signal is confirmed. Multilateral mechanisms exist on paper, but the operational lag between a confirmed signal and resources landing in an affected district remains the single largest driver of outbreak size.
One Health makes the financing case sharper, not softer
Mpox's animal reservoir, still not fully characterized, is exactly the kind of problem a One Health lens is built for. Framing the response purely as a human health emergency undercounts the investment case. Wildlife trade monitoring, veterinary surveillance in affected forest regions, and community-level education about animal contact all reduce spillover risk at a fraction of the cost of responding to established human-to-human transmission chains.
This is where public health diplomacy does real work. Multilateral funders are more willing to commit to prevention-side investment when it's framed as shared risk reduction rather than charity. Regional bodies like the Africa CDC have made this case effectively at the continental level; the opportunity now is translating it into durable, multi-year financing commitments rather than emergency-cycle funding that disappears once case counts drop.
What durable financing would look like
The countries that will fare best in the next zoonotic event are the ones building financing relationships now, before the next emergency, structured around shared surveillance infrastructure rather than single-disease response funds. That means moving conversations with international partners away from crisis appeals and toward standing investment in regional laboratory networks, veterinary-human data sharing systems, and community surveillance workforces that serve multiple disease priorities at once.
That shift doesn't happen through a grant proposal. It happens through sustained relationship-building between health ministries, finance ministries, and international partners, which is precisely the kind of work that gets neglected when everyone is focused on the current outbreak instead of the next one.